National and Kapodistrian University of Athens
Identifying new small molecule inhibitors for the therapy of chronic inflammatory diseases: developing of a novel screening pipeline
Abstract
dc:descriptionIn this work we aimed to identify new potential therapeutics against chronic inflammatory diseases, by developing of a novel screening pipeline, as current treatments are characterized by low patients’ response, invasive administration and a plethora of side effects.Initially, we considered a molecular docking approach searching for direct inhibitors of TNF trimerization, by using the Enalos Asclepios in silico pipeline, which has been used for identification of new therapeutics against TNF-mediated chronic inflammatory diseases, providing state-of-the-art insight on their binding mode. Focusing on a NPs library, we propose that Nepalensinol B, a stilbenoid that belongs to resveratrol dimers, characterized by low free energy of binding and by a high number of hydrogen bonds with TNF, qualifies as a potential lead compound for TNF inhibitors’ drug development, as it shows promising results in relevant ex vivo assays and it effectively interrupts TNF-TNFR1 binding. A similar molecular docking approach for identification of potential PPI inhibitors of TNF was applied in a library of FDA approved drugs. Pharmacological testing of the selected compounds, along with the application of the Enalos Asclepios pipeline, concluded in proposing Dilazep Dihydrochloride as a potent compound to down-regulate proinflammatory responses of hTNFtg pathogenic synovial fibroblasts and TNF induced necroptosis on L929 cells, while interrupting the TNF-TNFR1 binding. Because of non-consistent in vivo results, we then aimed to identify compounds starting from a more biologically relevant perspective, searching for compounds that could reverse deregulated gene expression signature of hTNFtg joints’ SFs. We identified that a neuroleptic medication, namely Amisulpride, could downregulate hTNFtg SFs’ activation and hTNFtg polyarthritis in vivo. Importantly, the molecular mechanism of the drug was not dependent on its main known receptors DRD2, DRD3 and HTR7. By applying a click chemistry approach, we identified two novel targets of the drug, namely ASCC3 and SEC62, which were further validated to repress hTNFtg SFs’ inflammatory potential. Thus, Amisulpride is proposed as a candidate for offering a combinatorial advantage to patients suffering from RA and comorbid depression. Finally, Amisulpride served as a lead compound for identification of novel, more potent therapeutics for chronic inflammatory disorders, which showed promising results ex vivo and in vivo. In conclusion, the pipeline we developed includes a combination of identification methods searching for new potential small molecule therapeutics, with a plethora of assays confirming the inhibitors’ action in silico, via the Enalos Asclepios pipeline, ex vivo in cell lines and primary cells, and in vivo in acute and chronic inflammation animal models. Potential targets of the compounds can be further identified following a click chemoproteomics approach.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadopoulou, Dimitra
- Παπαδοπούλου, Δήμητρα
Subjects
dc:subject × 8Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52394